Pauline Ho

Pauline Ho

Auto-generated profile, based on publicly available information

Pauline Ho

Kellgren Centre of Rheumatology, Manchester University NHS Foundation Trust, Manchester, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2017 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
MCMadhura Castelino
Madhura Castelino
SEStephen Eyre
Stephen Eyre
JMJohn Moat
John Moat
GFGraeme Fox
Graeme Fox
PMPaul Martin
Paul Martin
ABAnne Barton
Anne Barton
The composition of the skin microbiome is predicted to play a role in the development of conditions such as atopic eczema and psoriasis. 16S rRNA gene sequencing allows the investigation of bacterial microbiota. A significant challenge in this field is development of cost effective high throughput methodologies for the robust interrogation of the skin microbiota, where biomass is low. Here we describe validation of methodologies for 16S rRNA (ribosomal ribonucleic acid) gene sequencing from the skin microbiome, using the Illumina MiSeq platform, the selection of primer to amplify regions for sequencing and we compare results with the current standard protocols.. DNA was obtained from two low density mock communities of 11 diverse bacterial strains (with and without human DNA supplementation) and from swabs taken from the skin of healthy volunteers. This was amplified using primer pairs covering hypervariable regions of the 16S rRNA gene: primers 63F and 519R (V1-V3); and 347F and 803R (V3-V4). The resultant libraries were indexed for the MiSeq and Roche454 and sequenced. Both data sets were denoised, cleaned of chimeras and analysed using QIIME. There was no significant difference in the diversity indices at the phylum and the genus level observed between the platforms. The capture of diversity using the low density mock community samples demonstrated that the primer pair spanning the V3-V4 hypervariable region had better capture when compared to the primer pair for the V1-V3 region and was robust to spiking with human DNA. The pilot data generated using the V3-V4 region from the skin of healthy volunteers was consistent with these results, even at the genus level (Staphylococcus, Propionibacterium, Corynebacterium, Paracoccus, Micrococcus, Enhydrobacter and Deinococcus identified at similar abundances on both platforms). The results suggest that the bacterial community diversity captured using the V3-V4 16S rRNA hypervariable region from sequencing using the MiSeq platform is comparable to the Roche454 GS Junior platform. These findings provide evidence that the optimised method can be used in human clinical samples of low bacterial biomass such as the investigation of the skin microbiota.

5 September 2022 in Neuromuscular Disorders
Verified
Journal Article
Open access
SRSithara Ramdas
Sithara Ramdas
RHRyan Malcolm Hum
Ryan Malcolm Hum
APAbigail Price
Abigail Price
APAnna Paul
Anna Paul
JBJeremy Douglas, Percy Bland
Jeremy Douglas, Percy Bland
HJHeinz Jungbluth
Heinz Jungbluth
Myasthenia gravis (MG) is an antibody-mediated immune disorder of the neuromuscular junction. SARS-CoV-2 is now recognised as a trigger factor for autoimmune diseases and to cause immune-mediated dysregulation, likely due to molecular mimicry induced by viral antigens. SARS-CoV-2 vaccination, similarly, results in exposure to viral antigen. Here we report 7 cases of new-onset myasthenia gravis in timely association with SARS-CoV-2 vaccination, including the first paediatric case identified to date. We also reviewed the literature for other new-onset MG cases reported within 4 weeks of SARS-CoV-2 vaccination and discuss our findings in the context of altered (auto)immunity following SARS-CoV-2 vaccination and/or infection.

17 May 2015 in Current Rheumatology Reports
Verified
Journal Article
Open access
MJMeghna Jani
Meghna Jani
ABAnne Barton
Anne Barton
PHPauline Ho
Pauline Ho
TNF-blocking agents, non-biological disease-modifying anti-rheumatic drugs (nbDMARDs) and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed treatments in psoriatic arthritis. A large proportion of patients do not respond to these medications, although unfortunately clinically useful biomarkers that predict future response are currently lacking. Several candidate gene polymorphisms have been associated with responses to biologic therapies and nbDMARDs; however, replication and validation of these variants in large prospective psoriatic arthritis cohorts are required before translating these to clinical practice. In this review, we discuss the advances made in pharmacogenetics of treatment response in psoriatic arthritis to date, with focus on biologic therapies approved for use, nbDMARDs and NSAIDs, as well as outline emerging methodologies to obtain data that will help inform a future precision medicine approach in this condition.

17 January 2024 in Arthritis & Rheumatology
Verified
Journal Article
Open access
RHRyan M. Hum
Ryan M. Hum
SSSeema D. Sharma
Seema D. Sharma
MSMichael Stadler
Michael Stadler
SVSebastien Viatte
Sebastien Viatte
PHPauline Ho
Pauline Ho
ACAll Noar Collaborators
All Noar Collaborators
Objective: There is growing evidence that genetic data are of benefit in the rheumatology outpatient setting by aiding early diagnosis. A genetic probability tool (G‐PROB) has been developed to aid diagnosis has not yet been tested in a real‐world setting. Our aim was to assess whether G‐PROB could aid diagnosis in the rheumatology outpatient setting using data from the Norfolk Arthritis Register (NOAR), a prospective observational cohort of patients presenting with early inflammatory arthritis.Methods: Genotypes and clinician diagnoses were obtained from patients from NOAR. Six G‐probabilities (0%–100%) were created for each patient based on known disease‐associated odds ratios of published genetic risk variants, each corresponding to one disease of rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, spondyloarthropathy, gout, or “other diseases.” Performance of the G‐probabilities compared with clinician diagnosis was assessed.Results: We tested G‐PROB on 1,047 patients. Calibration of G‐probabilities with clinician diagnosis was high, with regression coefficients of 1.047, where 1.00 is ideal. G‐probabilities discriminated clinician diagnosis with pooled areas under the curve (95% confidence interval) of 0.85 (0.84–0.86). G‐probabilities 2 unlikely diseases for 94% of patients and >3 for 53.7% of patients. G‐probabilities >50% corresponded to a positive predictive value of 70.4%. In 55.7% of patients, the disease with the highest G‐probability corresponded to clinician diagnosis.Conclusion: G‐PROB converts complex genetic information into meaningful and interpretable conditional probabilities, which may be especially helpful at eliminating unlikely diagnoses in the rheumatology outpatient setting. image

25 December 2025 in EULAR Rheumatology Open
Verified
Journal Article
Open access
YTYvonne Tan
Yvonne Tan
GRGeorge Rogers
George Rogers
RSRudresh Shukla
Rudresh Shukla
PHPauline Ho
Pauline Ho
MBMaya H. Buch
Maya H. Buch
To evaluate the proportion of persistent inflammatory refractory rheumatoid arthritis (PIRRA) and noninflammatory refractory rheumatoid arthritis (NIRRA) of difficult-to-treat rheumatoid arthritis (D2T-RA) using musculoskeletal ultrasound (MSUS) and to compare clinical characteristics across PIRRA, NIRRA, and disease-controlled refractory rheumatoid arthritis (RA) subgroups. A retrospective single-centre cohort study identified patients (May 2021 to December 2022) with inadequate response to ≥2 different mechanism of action biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and disease activity score in 28 joints-erythrocyte sedimentation rate (ESR) of >3.2 as European Alliance of Associations for Rheumatology-defined D2T-RA. MSUS classified this group into PIRRA (power Doppler present) or NIRRA (no power Doppler synovitis). A comparator group of controlled refractory RA (≥2 b/tsDMARD failures but sustained low disease activity) was also assessed. Clinical data were collected and analysed. Of the 85 patients, 45 had D2T-RA (25 [56%] PIRRA; 20 [44%] NIRRA), and 40 had controlled refractory RA. PIRRA subgroup had higher C-reactive protein (CRP), but NIRRA subgroup higher ESR. Fibromyalgia was more prevalent in PIRRA and NIRRA than that in controlled refractory RA (48%, 40%, and 17.5%, respectively; P = .02). Nearly half of patients in the controlled refractory group (17/37 [46%]) had subclinical synovitis on MSUS. Rates of radiographic erosions were similar across PIRRA, NIRRA, and controlled refractory groups. MSUS-based stratification of D2T-RA into PIRRA and NIRRA reveals distinct associations to CRP and ESR and comparable chronic pain. Subclinical inflammation is present even in ostensibly controlled disease, suggesting risk of re-falling into an active D2T-RA state. Identifying such subphenotypes can inform on monitoring strategies, support mechanistic investigation, and enable more targeted treatments to improve outcomes of D2T-RA.

9 November 2026 in medRxiv
Verified
Preprint
Open access
PDF file
RHRyan Malcolm Hum
Ryan Malcolm Hum
MCMaria Christofi
Maria Christofi
SSSamantha L Smith
Samantha L Smith
YTYvonne Tan
Yvonne Tan
RSRudresh Shukla
Rudresh Shukla
PMPaul Martin
Paul Martin
Background: Synovial inflammation in psoriatic arthritis (PsA) lacks a validated histological classification framework. Current approaches apply rheumatoid arthritis (RA) synovial pathotypes to PsA, which overlooks immunobiological differences between the diseases and limits the predictive power of tissue stratification. We aimed to define data-driven, PsA-specific synovial pathotypes to facilitate tissue-driven precision medicine. Methods: In this cross-sectional study, ultrasound-guided synovial biopsies were obtained from 61 patients with PsA (n=22), seropositive RA (n=23), seronegative RA (n=10), and other inflammatory arthritides (n=6). Sections underwent multi-modal staining, including H&E, picrosirius red, and immunohisto-chemistry for CD3, CD20, CD68, CD138, and CD31. Whole-slide digital image analysis and automated pixel classifiers quantified cellular and stromal metrics. Unsupervised hierarchical clustering identified intrinsic PsA pathotypes, which were correlated with clinical disease activity, radiographic osteoarthritis (OA), and longitudinal treatment responses. Findings: While a subset of PsA patients shared an inflammatory signature with seropositive RA, unsupervised clustering of the PsA cohort revealed three distinct, novel pathotypes: ‘Dense Myeloid’ (macrophage-driven), ‘Fibro-Stromal’ (fibrosis and pauci-immune), and ‘Angio-Lymphoid’ (hypervascular with significant CD138 + plasma cell infiltration). Pathotypes were independent of treatment and concurrent radiographic knee OA. The Fibro-Stromal pathotype correlated with significantly higher cutaneous psoriasis severity. Longitudinally, patients with the Fibro-Stromal pathotype exhibited a trend toward lower treatment response (44%) following standard interventions (methotrexate or TNF inhibitors) compared to the Dense Myeloid (50%) and Angio-Lymphoid (80%) pathotypes. Interpretation: We present the first computationally derived synovial pathotypes specific to PsA, revealing distinct plasma cell and fibrotic architectures not captured by RA-centric models. To enable clinical translation, we distilled these findings into a pragmatic, four-marker diagnostic decision tree (CD31, CD68, CD138, and picrosirius red) designed for routine histopathology workflows, providing a staging ground for biomarker-stratified clinical trials in PsA. Funding: Funding from the NIHR Biomedical Research Centre: Manchester, Arthritis UK, the Wellcome Trust, Brit-PACT, the National Psoriasis Foundation, and the Medical Research Council. Research in context: Evidence before this study: The potential clinical utility of tissue-based patient stratification is well established in rheumatoid arthritis (RA), where baseline synovial pathotypes (lympho-myeloid, diffuse-myeloid, and pauciimmune) have guided targeted biologic therapy in landmark precision medicine trials. However, psoriatic arthritis (PsA) exhibits a fundamentally distinct synovial microenvironment, characterised by unique vascular architecture, altered stromal fibroblast phenotypes, and distinct immune infiltrates intertwined with the IL-23/IL-17 cytokine axis. Consequently, attempting to classify PsA synovial tissue using established RA-derived scoring systems risks misrepresenting intrinsic disease biology. There is currently no validated, disease-specific histological classification system for PsA, which forces therapeutic decision-making to rely on an empirical, trial-and-error approach rather than underlying target tissue pathobiology. Added value of this study: To our knowledge, this is the first study to define data-driven, computationally derived synovial pathotypes entirely specific to PsA. By leveraging multi-modal digital pathology and unsupervised machine learning, we deconstructed the PsA synovium into three biologically distinct pathotypes: Dense Myeloid, Fibro-Stromal, and Angio-Lymphoid. We demonstrated that the highly inflammatory PsA microenvironment is distinctly driven by CD138 + plasma cells rather than the CD20 + B cells typically observed in RA. Furthermore, we identified a striking tissue-level divergence: patients with the highly fibrotic, pauci-immune Fibro-Stromal pathotype exhibited the most severe cutaneous psoriasis and demonstrated a trend toward higher failure rates on standard therapies, independent of concurrent osteoarthritis. Crucially, we translated these high-dimensional computational findings into a pragmatic, four-marker diagnostic decision tree (incorporating CD31, CD68, CD138, and picrosirius red). Implications of all the available evidence: This study establishes that PsA synovial pathology requires a dedicated, disease-specific classification framework. The proposed diagnostic decision tree can be integrated into routine clinical histopathology workflows without the immediate need for advanced spatial or single-cell transcriptomics. Furthermore, the correlation between the Fibro-Stromal pathotype, severe skin disease, and poor joint response to standard therapies provides a biological rationale for stratifying this specific subgroup towards early IL-17 or IL-23 inhibitor intervention alongside conventional synthetic disease-modifying antirheumatic drugs. Ultimately, these novel PsA pathotypes provide the vital staging ground required to design and execute biomarker-stratified, tissue-driven clinical trials, paving the way for precision medicine in PsA.